SEC Looks Into Dendreon Following FDA Disclosure

Law360, New York (July 10, 2007, 12:00 AM EDT) -- Biotechnology company Dendreon Corp. said Tuesday that the U.S. Securities and Exchange Commission has opened an informal inquiry into the company's clinical trials for its prostate cancer drug, Provenge.

The inquiry comes on the heels of the U.S. Food and Drug Administration seeking more information from the company on the drug, a move that prompted a handful of shareholder lawsuits.

In a filing with the SEC Tuesday, Dendreon said that the New York Regional Office of the SEC notified the company on Monday that it was...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.